Toxoplasma gondii and Cryptosporidium parvum cause fatal infections in persons immune compromised by AIDS. For AIDS patients, there is essentially no effective therapy against C. parvum and limited therapeutic options for T. gondii. The lack of treatment options against C. parvum is largely due to the fact that C. parvum cannot be propagated in cell culture. In contrast, T. gondii is easily propagated in cell culture and has a wealth of molecular genetic tools available for its analysis. Our goals have been to perform functional genomics on T. gondii to uncover virulence genes. For this goal, we adapted signature-tagged mutagenesis (STM) to T. gondii, and screened a library of over 6300 insertion mutants. From this library we isolated 39 avirulent clones and we have identified the gene disrupted in 34 avirulent mutants. For this proposal, we will examine six mutants uncovered in the STM screen that are disrupted in genes with orthologous sequences in C. parvum. Because C. parvum does not contain a chronic cyst stage of infection, we want to focus on mutants that are defective during acute infection.
The first aim will determine the contribution of the disrupted genes to acute infection for these six mutants. We will then choose two mutants for complementation studies by re-expression of the disrupted T. gondii gene or expression of the C. parvum ortholog from a T. gondii promoter. These experiments will allow us to confirm the contribution to acute virulence of the disrupted gene and to determine if the C. parvum ortholog is functionally analogous. This proposal will allow us to exploit the power of T. gondii molecular genetics to uncover C. parvum virulence genes. This research may discover new drug targets for both T. gondii and C. parvum, and create tools for the study of potential inhibitors.

Public Health Relevance

Toxoplasma gondii and Cryptosporidium parvum cause fatal infections in persons immune-compromised by AIDS, with little or no effective therapeutic options currently available. The lack of treatment against C. parvum is largely due to the fact that C. parvum cannot be propagated in cell culture. This proposal will allow us to exploit the power of T. gondii molecular genetics to uncover C. parvum virulence genes, and may result in the discovery of new drug targets for both T. gondii and C. parvum.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Research Grants (R03)
Project #
5R03AI077345-02
Application #
7569997
Study Section
AIDS-associated Opportunistic Infections and Cancer Study Section (AOIC)
Program Officer
Mcgugan, Glen C
Project Start
2008-03-01
Project End
2011-02-28
Budget Start
2009-03-01
Budget End
2011-02-28
Support Year
2
Fiscal Year
2009
Total Cost
$69,740
Indirect Cost
Name
University of Wisconsin Madison
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Milligan-Myhre, Kathryn; Wilson, Sarah K; Knoll, Laura J (2016) Developmental change in translation initiation alters the localization of a common microbial protein necessary for Toxoplasma chronic infection. Mol Microbiol 102:1086-1098
Tobin, Crystal M; Knoll, Laura J (2012) A patatin-like protein protects Toxoplasma gondii from degradation in a nitric oxide-dependent manner. Infect Immun 80:55-61
Rooney, Peggy J; Ayong, Lawrence; Tobin, Crystal M et al. (2011) TgVTC2 is involved in polyphosphate accumulation in Toxoplasma gondii. Mol Biochem Parasitol 176:121-6
Milligan-Myhre, Kathy C; Rooney, Peggy J; Knoll, Laura J (2011) Examination of a virulence mutant uncovers the ribosome biogenesis regulatory protein of Toxoplasma gondii. J Parasitol 97:1173-7